PANEL DISCUSSION: An Overview of Emerging Therapeutic Targets
Time: 6:05 pm
day: Day One
Details:
- Examine the current treatment options and emerging targeted therapies
- If targeted therapies show limited efficacy as single agents, can the combination of several targeted therapies be of benefit to GBM patients?
- Additional research is urgently required to identify therapeutic targets in GBM: How can the industry design novel therapeutic strategies for the treatment of GBM?
Speakers:
Dr. Skolnik oversees all of Inovio’s cancer immunotherapy programs, as well as those for several infectious diseases. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He was also a Medical Affairs lead…Read more
Dr. Ranjit Bindra is a physician-scientist at the Yale School of Medicine and Co-Director of the Yale Brain Tumor Center. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to…Read more
William F. Elmquist is currently Professor and Director of the Brain Barriers Research Center, at the University of Minnesota, Department of Pharmaceutics. He received his pharmacy degree at the University of Florida, and Pharm.D. and Ph.D. (pharmacokinetics) from the University of Minnesota. His research has studied the influence of active efflux transporters in the blood-brain…Read more